Outcomes of Patients with Borderline Resectable Pancreatic Cancer Treated with Combination Chemotherapy
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Gastrointestinal Cancer"
DOI: 10.1007/s12029-020-00417-9
Abstract: Background Patients with borderline resectable pancreatic cancer are at high risk of incomplete resection with upfront surgery. Currently, no standard induction chemotherapy regimen exists for these patients. Both FOLFIRINOX (5-FU, irinotecan, & oxaliplatin) and gemcitabine… read more here.
Keywords: patients borderline; folfirinox gnp; resectable pancreatic; pancreatic cancer ... See more keywords
Outcomes of patients with borderline-resectable pancreatic cancer treated with FOLFIRINOX versus gemcitabine plus nab-paclitaxel.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.4_suppl.299
Abstract: 299 Background: Pancreatic cancer is a major cause of cancer-related death. Less than 20% of patients have resectable disease at diagnosis. Patients with borderline-resectable pancreatic cancer (BRPC) are at high risk of incomplete resection with… read more here.
Keywords: cancer; study; gemcitabine; folfirinox gnp ... See more keywords